Condition: Relapsed/Refractory Multiple Myeloma (MM) · Sponsor: Hadassah Medical Organization
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
This description comes directly from the study's public registry record.
Polina Stepensky, MD · 972-2-6778353 · Fainak@hadassah.org.il
Always discuss trial participation with your own doctor first.
| Hadassah MO, Jerusalem, 9574869 | Jerusalem, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07333430